NewsBenzingaReported Saturday, Agenus Says 25% Of Recurrent Ovarian Cancer Patients Treated With BOT+BAL Were Alive And Off All Therapy At Last Follow-Up, With 48% Estimated Three-Year Survival Among Evaluable Patients Reported Saturday, Agenus Says 25% Of Recurrent Ovarian Cancer Patients Treated With BOT+BAL Were Alive And Off All Therapy At Last Follow-Up, With 48% Estimated Three-Year Survival Among Evaluable Patients Benzinga 2026.10.05 06:57 (GMT+0) Open on Benzinga Other news Morgan Stanley Upgrades Wells Fargo to Overweight, Maintains Price Target to $102 Vivek Ramaswamy-Founded Strive to Acquire More Bitcoin? Here's What the CEO Hinted at BMO Capital Initiates Coverage On Vertiv Holdings with Outperform Rating, Announces Price Target of $329 BMO Capital Initiates Coverage On nVent Electric with Outperform Rating, Announces Price Target of $212 Sweetgreen Q2 2026 Earnings Call: Complete Transcript Gen Digital Q1 2027 Earnings Call: Complete Transcript
BMO Capital Initiates Coverage On Vertiv Holdings with Outperform Rating, Announces Price Target of $329
BMO Capital Initiates Coverage On nVent Electric with Outperform Rating, Announces Price Target of $212
